Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of “Moderate Buy” from Analysts

Pfizer Inc. (NYSE:PFE) has received an average recommendation of “Moderate Buy” from the fifteen analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, three have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $29.17.

Several equities research analysts have commented on PFE shares. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target for the company. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Rialto Wealth Management LLC purchased a new position in Pfizer in the 4th quarter valued at approximately $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer in the 4th quarter valued at approximately $27,000. Gould Capital LLC grew its stake in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the 1st quarter valued at approximately $27,000. Finally, Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the 4th quarter valued at $28,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.0%

NYSE:PFE opened at $23.46 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $133.38 billion, a price-to-earnings ratio of 16.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.54. The firm has a 50-day moving average price of $23.12 and a two-hundred day moving average price of $25.05.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.82 EPS. On average, equities analysts expect that Pfizer will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.33%. Pfizer’s dividend payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.